Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRTNASDAQ:RPTXNYSEAMERICAN:SYNNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.63+2.4%$0.64$0.51▼$1.80$60.52M0.29657,658 shs228,019 shsRPTXRepare Therapeutics$1.47+1.2%$1.30$0.89▼$4.29$62.92M0.84253,068 shs37,176 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shsUNCYUnicycive Therapeutics$0.68+6.8%$0.62$0.20▼$1.10$82.20M2.011.96 million shs4.32 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%-4.52%-1.19%-12.52%-39.24%RPTXRepare Therapeutics0.00%-0.20%+10.30%+33.36%-63.23%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%UNCYUnicycive Therapeutics0.00%-9.68%+23.76%+16.48%+3.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASRTAssertio2.2337 of 5 stars3.51.00.00.02.70.81.3RPTXRepare Therapeutics2.7201 of 5 stars3.33.00.00.02.72.50.6SYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/AUNCYUnicycive Therapeutics3.5592 of 5 stars3.85.00.00.03.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 3.00Buy$2.75335.20% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50206.75% UpsideSYNSynthetic Biologics 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.50Strong Buy$6.00780.54% UpsideCurrent Analyst Ratings BreakdownLatest SYN, UNCY, RPTX, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$9.005/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.505/13/2025ASRTAssertioAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.503/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.50(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$119.00M0.51$0.56 per share1.12$1.46 per share0.43RPTXRepare Therapeutics$1.07M58.64N/AN/A$5.03 per share0.29SYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/AUNCYUnicycive Therapeutics$680K120.88N/AN/A($0.11) per share-6.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$331.94M-$0.32N/A21.063.25-54.46%3.79%1.81%8/6/2025 (Estimated)RPTXRepare Therapeutics-$93.80M-$3.01N/AN/AN/A-99.76%-40.87%-35.07%N/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/AUNCYUnicycive Therapeutics-$30.54M-$0.51N/AN/AN/AN/AN/A-29.88%N/ALatest SYN, UNCY, RPTX, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025UNCYUnicycive Therapeutics-$0.14-$0.05+$0.09-$0.05N/AN/A5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.302.011.57RPTXRepare TherapeuticsN/A6.456.45SYNSynthetic BiologicsN/A4.144.14UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%RPTXRepare Therapeutics85.09%SYNSynthetic Biologics74.38%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%RPTXRepare Therapeutics11.50%SYNSynthetic Biologics2.15%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2095.78 million92.42 millionOptionableRPTXRepare Therapeutics18042.89 million33.33 millionOptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableUNCYUnicycive Therapeutics9120.63 million78.78 millionNot OptionableSYN, UNCY, RPTX, and ASRT HeadlinesRecent News About These CompaniesUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in MayJune 15 at 10:09 AM | marketbeat.comBrookline Capital Management Weighs in on UNCY Q3 EarningsJune 14 at 1:45 AM | americanbankingnews.comUNCY Q3 EPS Forecast Raised by Brookline Capital ManagementJune 12 at 7:52 AM | marketbeat.comKaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law ViolationsJune 11, 2025 | theglobeandmail.comRetail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28mJune 11, 2025 | finance.yahoo.comUnicycive Shares Slide as FDA Flags Issues Related to Kidney Drug ApplicationJune 10, 2025 | marketwatch.comUnicycive Therapeutics stock tumbles after FDA flags manufacturing issuesJune 10, 2025 | investing.comUnicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025June 10, 2025 | quiverquant.comUnicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisJune 10, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short InterestJune 3, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for UNCY Q2 Earnings?May 30, 2025 | marketbeat.comQ4 Earnings Estimate for UNCY Issued By HC WainwrightMay 29, 2025 | marketbeat.comUnicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC WainwrightMay 28, 2025 | marketbeat.comUnicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor ConferencesMay 22, 2025 | quiverquant.comUnicycive Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comUnicycive Therapeutics Announces Time Change for 2025 Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comQ2 Earnings Forecast for UNCY Issued By Noble FinancialMay 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Acquired by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deUnicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comAnalysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before LongMay 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSynopsys Stock Falls on China Ban, But Long-Term Outlook HoldsBy Leo Miller | June 14, 2025View Synopsys Stock Falls on China Ban, But Long-Term Outlook HoldsSYN, UNCY, RPTX, and ASRT Company DescriptionsAssertio NASDAQ:ASRT$0.63 +0.02 (+2.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.62 -0.01 (-2.36%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Repare Therapeutics NASDAQ:RPTX$1.47 +0.02 (+1.17%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.44 -0.03 (-1.84%) As of 06/13/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.Unicycive Therapeutics NASDAQ:UNCY$0.68 +0.04 (+6.82%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.23%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
